ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
ZAGAL Study: Evaluating Effectiveness and Tolerability of Zonisamide as Adjunctive Therapy in Patients With Partial Onset Seizures Treated With Two Antiepileptic Drugs
The purpose of this study is to acquire additional information about the appropriate level of
 dosing of Zonisamide when it is prescribed for patients with partial onset epileptic crisis
 who are already being treated with two other antiepileptic drugs.
Patients from both sexes, 18 to 65 years of age, diagnosed with simple or complex partial
 onset epileptic crisis defined according to the International League Against Epilepsy (ILAE)
 criteria, with a minimum of two seizures within the 4 previous weeks, a stable treatment with
 two antiepileptic drugs for at least 12 weeks, and capable and willing to give their informed
 consent, will be included in the study.

 To these patients, physicians will prescribe zonisamide in the following manner: Titration
 period of 12 weeks, at the end of which all patients must be taking 300 mg. Maintenance doses
 period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose
 from the titration period, lower it to 200 mg, or take it up to 400 mg. Six weeks later
 within this period, a decision will be made to raise the 400 mg doses up to 500 mg if
 considered necessary and tolerable.

 Drugs will be prescribed by the physician and purchased by the patient.
Inclusion Criteria:

 Patients from both sexes, 18 to 65 years of age, diagnosed with simple or complex partial
 onset epileptic seizures defined according to the International League Against Epilepsy
 (ILAE) criteria, with a minimum of two crises within the 4 previous weeks, a stable
 treatment with two antiepileptic drugs for at least 12 weeks and capable and willing to
 give their informed consent, will be included.

 Exclusion Criteria:

 Those who do not fulfill the Inclusion requirements.